ENSC Ensysce Biosciences, Inc.
Healthcare$0.32-1.39%ClosedMarket Cap: $3.0M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
-6.41
P/S
1.05
EV/EBITDA
-0.39
DCF Value
$156,537.01
FCF Yield
-328.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-72.9%
Operating Margin
-418.9%
Net Margin
-417.1%
ROE
-631.5%
ROA
-543.7%
ROIC
2797.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $961.0K | 99.3% | $-3.6M | $-3.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.8M | $-2.8M | $— | — |
| FY null | $5.1M | 0.0% | $-10.2M | $-10.2M | $— | — |
| Q3 null | $493.1K | -499.2% | $-3.7M | $-3.7M | $— | — |
| Q2 null | $1.4M | -40.2% | $-1.8M | $-1.7M | $— | — |
| Q1 null | $1.3M | 100.0% | $-2.0M | $-1.9M | $— | — |
| Q4 null | $1.3M | -191.7% | $-3.6M | $-3.6M | $— | — |
| FY null | $5.2M | -38.6% | $-6.7M | $-8.0M | $— | — |
| Q3 null | $3.4M | 50.5% | $644.7K | $661.8K | $— | — |
| Q2 null | $181.8K | -421.0% | $-2.0M | $-2.0M | $— | — |
| Q1 null | $305.7K | -154.7% | $-1.8M | $-3.1M | $— | — |
| Q4 2023 | $515.0K | -333.5% | $-3.2M | $-3.5M | $-1.55 | — |